Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others.

J Law Med Ethics

Esther Bettiol, M.D., Ph.D., is Scientific Officer for the DRIVE-AB project at the University of Geneva, Geneva, Switzerland. She has an M.D. and a Ph.D. from the University of Geneva. Judith Hackett, M.B.A., is Global Director, Pricing and Reimbursement INFECTION at AstraZeneca in Gaithersburg, MD. She has a B.S.C. P.H.M. degree from the University of Toronto (Canada), an M.B.A. from the Schulich School of Business (York University, Toronto), and a Diploma in Health Economics from the University of Toronto. Stephan Harbarth, M.D., M.S., is an Associate Professor and Senior Consultant, Attending in Geriatric and General Infectious Diseases, and Associate Hospital Epidemiologist at the Geneva University Hospitals and Faculty of Medicine in Geneva, Switzerland.

Published: June 2018

Global discussions are ongoing on how to stimulate antibiotic research and development in order to provide patients with new antibiotics able to address the challenges of antimicrobial resistance. In this supplement, we present nine articles derived from the research performed as part of the Innovative Medicine Initiative-funded DRIVE-AB project and others. These publications provide new evidence and arguments in the debate around economic incentives to stimulate antibiotic innovation, including characteristics, implementation and governance.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1073110518782910DOI Listing

Publication Analysis

Top Keywords

drive-ab project
8
stimulate antibiotic
8
stimulating development
4
development antibiotics
4
antibiotics ensuring
4
ensuring sustainable
4
sustainable access
4
access insights
4
insights drive-ab
4
project global
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!